BR112013017977A2 - formas sólidas de inibidor de girase (r) 1-etil-3-[5-[2-{1-hidroxi-1-metil-etil}pirimidin-5-il]-7-(tetrai-drofuran-2-il)-1h-benzimidazol-2-il]ureia - Google Patents
formas sólidas de inibidor de girase (r) 1-etil-3-[5-[2-{1-hidroxi-1-metil-etil}pirimidin-5-il]-7-(tetrai-drofuran-2-il)-1h-benzimidazol-2-il]ureiaInfo
- Publication number
- BR112013017977A2 BR112013017977A2 BR112013017977A BR112013017977A BR112013017977A2 BR 112013017977 A2 BR112013017977 A2 BR 112013017977A2 BR 112013017977 A BR112013017977 A BR 112013017977A BR 112013017977 A BR112013017977 A BR 112013017977A BR 112013017977 A2 BR112013017977 A2 BR 112013017977A2
- Authority
- BR
- Brazil
- Prior art keywords
- ethyl
- solid forms
- benzimidazol
- pyrimidin
- tetrahydrofuran
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
formas sólidas de inibidor de girase (r) 1-etil-3-[5-[2-{1-hidroxi-1-metil-etil}pirimidin-5-il]-7-(tetrai-drofuran-2-il)-1h-benzimidazol-2-il]ureia o presente pedido refere-se a formas sólidas de compostos de fórmula (i) e sais farmaceuticamente aceitáveis dos mesmos que inibem girase bacteriana e/ou topo iv e composições farmacêuticas compreendendo os ditos compostos e sais. esses compostos e sais são úteis no tratamento de infecção bacteriana.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161433161P | 2011-01-14 | 2011-01-14 | |
PCT/US2012/021275 WO2012097270A1 (en) | 2011-01-14 | 2012-01-13 | Solid forms of gyrase inhibitor (r)-1-ethyl-3-[5-[2-{1-hydroxy-1-methyl-ethyl}pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl}-1h-benzimidazol-2-yl]urea |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013017977A2 true BR112013017977A2 (pt) | 2019-09-24 |
Family
ID=45615044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013017977A BR112013017977A2 (pt) | 2011-01-14 | 2012-01-13 | formas sólidas de inibidor de girase (r) 1-etil-3-[5-[2-{1-hidroxi-1-metil-etil}pirimidin-5-il]-7-(tetrai-drofuran-2-il)-1h-benzimidazol-2-il]ureia |
Country Status (17)
Country | Link |
---|---|
US (2) | US8481552B2 (pt) |
EP (1) | EP2663558A1 (pt) |
JP (1) | JP2014507413A (pt) |
KR (1) | KR101897950B1 (pt) |
CN (1) | CN103384666A (pt) |
AR (1) | AR084862A1 (pt) |
AU (1) | AU2012205416B2 (pt) |
BR (1) | BR112013017977A2 (pt) |
CA (1) | CA2824401A1 (pt) |
CL (1) | CL2013002026A1 (pt) |
IL (1) | IL227407B (pt) |
MX (1) | MX351555B (pt) |
RU (1) | RU2013137753A (pt) |
SG (1) | SG191924A1 (pt) |
TW (1) | TW201309676A (pt) |
WO (1) | WO2012097270A1 (pt) |
ZA (1) | ZA201305230B (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012205419B2 (en) * | 2011-01-14 | 2016-12-15 | Spero Therapeutics, Inc. | Solid forms of gyrase inhibitor (R)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl) pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1H-benzimidazol-2-yl]urea |
AU2012205420B2 (en) * | 2011-01-14 | 2016-12-08 | Spero Therapeutics, Inc. | Process of making gyrase and topoisomerase IV inhibitors |
TW201309676A (zh) | 2011-01-14 | 2013-03-01 | Vertex Pharma | 旋轉酶抑制劑(r)-1-乙基-3-[5-[2-(1-羥基-1-甲基-乙基)嘧啶-5-基]-7-(四氫呋喃-2-基]-1h-苯并咪唑-2-基]脲之固體形式 |
EP2663557B1 (en) * | 2011-01-14 | 2015-05-27 | Vertex Pharmaceuticals Incorporated | Pyrimidine gyrase and topoisomerase iv inhibitors |
JP5977344B2 (ja) * | 2011-06-20 | 2016-08-24 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | ジャイレースおよびトポイソメラーゼ阻害剤のリン酸エステル |
WO2014014845A1 (en) * | 2012-07-18 | 2014-01-23 | Vertex Pharmaceuticals Incorporated | Combination therapy comprising|1 -ethyl-3-[5-[2-{1 -hydroxy-1 -methyl-ethyl}pyrimidin-5-yl]-7-(tetra hydrofuran-2-|yl}-1 h-benzimidazol-2-yl]urea and derivatives thereof to treat mycobacterium|diseases |
US9018216B2 (en) * | 2012-07-18 | 2015-04-28 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof |
CA2938459A1 (en) * | 2014-02-03 | 2015-08-06 | Spero Gyrase, Inc. | Antibacterial compounds |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2015676A1 (de) | 1970-04-02 | 1971-10-21 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Neue Imine der 2-Formyl-chinoxalindi-N-oxidcarbon-säure-(3) und deren Salze, Verfahren zu ihrer Herstellung und ihre Verwendung als antimikrobielle Mittel |
US4174400A (en) | 1978-09-13 | 1979-11-13 | Merck & Co., Inc. | Anthelmintic benzimidazoles |
US4512998A (en) | 1980-10-20 | 1985-04-23 | Schering Corporation | Anthelmintic benzimidazole carbamates |
CA2028530A1 (en) | 1989-11-21 | 1991-05-22 | Christian Hubschwerlen | Substituted pyrimidobenzimidazole derivatives |
DE19514313A1 (de) | 1994-08-03 | 1996-02-08 | Bayer Ag | Benzoxazolyl- und Benzothiazolyloxazolidinone |
HRP960159A2 (en) | 1995-04-21 | 1997-08-31 | Bayer Ag | Benzocyclopentane oxazolidinones containing heteroatoms |
US5643935A (en) | 1995-06-07 | 1997-07-01 | The University Of North Carolina At Chapel Hill | Method of combatting infectious diseases using dicationic bis-benzimidazoles |
TW538046B (en) | 1998-01-08 | 2003-06-21 | Hoechst Marion Roussel Inc | Aromatic amides having antiobiotic activities and the preparation processes, intermediates and pharmaceutical composition thereof |
AUPP873799A0 (en) | 1999-02-17 | 1999-03-11 | Fujisawa Pharmaceutical Co., Ltd. | Pyridine compounds |
GB9911594D0 (en) | 1999-05-19 | 1999-07-21 | Smithkline Beecham Plc | Novel compounds |
GB9912413D0 (en) | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
MY138797A (en) * | 2000-12-15 | 2009-07-31 | Vertex Pharma | Bacterial gyrase inhibitors and uses thereof |
MXPA04012628A (es) | 2002-06-13 | 2005-03-23 | Patricia Olivershaffer | DERIVADOS Y COMPUESTOS RELACIONADOS DEL áCIDO 2-UREIDO-6-HETEROARIL-3H-BENZOIMIDAZOL-4-CARBOXILICO COMO INHIBIDORES DE GIRASA Y/O TOPOISOMERASA IV PARA EL TRATAMIENTO DE INFECCIONES BACTERIALES. |
US7569591B2 (en) | 2003-01-31 | 2009-08-04 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
US8404852B2 (en) | 2003-01-31 | 2013-03-26 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
US7618974B2 (en) | 2003-01-31 | 2009-11-17 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
US7582641B2 (en) | 2003-01-31 | 2009-09-01 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
US8193352B2 (en) | 2003-01-31 | 2012-06-05 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
AR042956A1 (es) | 2003-01-31 | 2005-07-13 | Vertex Pharma | Inhibidores de girasa y usos de los mismos |
WO2007056330A1 (en) | 2005-11-07 | 2007-05-18 | Vertex Pharmaceuticals Incorporated | Benzimidazole derivatives as gyrase inhibitors |
US8481544B2 (en) | 2006-06-22 | 2013-07-09 | Biota Europe Limited | Antibacterial compositions |
GB0612428D0 (en) | 2006-06-22 | 2006-08-02 | Prolysis Ltd | Antibacterial agents |
GB0724349D0 (en) | 2007-12-13 | 2008-01-30 | Prolysis Ltd | Antibacterial agents |
EP2102199B1 (en) | 2006-12-04 | 2011-04-27 | AstraZeneca AB | Antibacterial polycyclic urea compounds |
GB0724342D0 (en) | 2007-12-13 | 2008-01-30 | Prolysis Ltd | Anitbacterial compositions |
WO2009156966A1 (en) | 2008-06-25 | 2009-12-30 | Ranbaxy Laboratories Limited | Benzothiazoles and aza-analogues thereof use as antibacterial agents |
EP2475666A2 (en) | 2009-09-11 | 2012-07-18 | Trius Therapeutics, Inc. | Gyrase inhibitors |
CN102725274A (zh) | 2009-10-16 | 2012-10-10 | Rib-X制药公司 | 抗微生物化合物和其制备和使用方法 |
US9181234B2 (en) | 2010-10-08 | 2015-11-10 | Biota Europe Ltd. | Antibacterial compounds |
AU2012205420B2 (en) * | 2011-01-14 | 2016-12-08 | Spero Therapeutics, Inc. | Process of making gyrase and topoisomerase IV inhibitors |
AU2012205419B2 (en) * | 2011-01-14 | 2016-12-15 | Spero Therapeutics, Inc. | Solid forms of gyrase inhibitor (R)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl) pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1H-benzimidazol-2-yl]urea |
TW201309676A (zh) | 2011-01-14 | 2013-03-01 | Vertex Pharma | 旋轉酶抑制劑(r)-1-乙基-3-[5-[2-(1-羥基-1-甲基-乙基)嘧啶-5-基]-7-(四氫呋喃-2-基]-1h-苯并咪唑-2-基]脲之固體形式 |
EP2663557B1 (en) * | 2011-01-14 | 2015-05-27 | Vertex Pharmaceuticals Incorporated | Pyrimidine gyrase and topoisomerase iv inhibitors |
JP5977344B2 (ja) * | 2011-06-20 | 2016-08-24 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | ジャイレースおよびトポイソメラーゼ阻害剤のリン酸エステル |
US9018216B2 (en) * | 2012-07-18 | 2015-04-28 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof |
WO2014014845A1 (en) * | 2012-07-18 | 2014-01-23 | Vertex Pharmaceuticals Incorporated | Combination therapy comprising|1 -ethyl-3-[5-[2-{1 -hydroxy-1 -methyl-ethyl}pyrimidin-5-yl]-7-(tetra hydrofuran-2-|yl}-1 h-benzimidazol-2-yl]urea and derivatives thereof to treat mycobacterium|diseases |
-
2012
- 2012-01-13 TW TW101101501A patent/TW201309676A/zh unknown
- 2012-01-13 US US13/349,845 patent/US8481552B2/en active Active
- 2012-01-13 JP JP2013549576A patent/JP2014507413A/ja active Pending
- 2012-01-13 RU RU2013137753/04A patent/RU2013137753A/ru not_active Application Discontinuation
- 2012-01-13 AU AU2012205416A patent/AU2012205416B2/en active Active
- 2012-01-13 SG SG2013053152A patent/SG191924A1/en unknown
- 2012-01-13 BR BR112013017977A patent/BR112013017977A2/pt not_active IP Right Cessation
- 2012-01-13 EP EP12704453.5A patent/EP2663558A1/en not_active Withdrawn
- 2012-01-13 MX MX2013008163A patent/MX351555B/es active IP Right Grant
- 2012-01-13 CN CN201280009904XA patent/CN103384666A/zh active Pending
- 2012-01-13 CA CA2824401A patent/CA2824401A1/en not_active Abandoned
- 2012-01-13 KR KR1020137018401A patent/KR101897950B1/ko active IP Right Grant
- 2012-01-13 WO PCT/US2012/021275 patent/WO2012097270A1/en active Application Filing
- 2012-01-16 AR ARP120100139A patent/AR084862A1/es unknown
-
2013
- 2013-06-06 US US13/911,483 patent/US20130317222A1/en not_active Abandoned
- 2013-07-10 IL IL227407A patent/IL227407B/en active IP Right Grant
- 2013-07-11 ZA ZA2013/05230A patent/ZA201305230B/en unknown
- 2013-07-12 CL CL2013002026A patent/CL2013002026A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2014507413A (ja) | 2014-03-27 |
NZ612912A (en) | 2015-10-30 |
CA2824401A1 (en) | 2012-07-19 |
US8481552B2 (en) | 2013-07-09 |
CN103384666A (zh) | 2013-11-06 |
KR20140037029A (ko) | 2014-03-26 |
KR101897950B1 (ko) | 2018-09-12 |
SG191924A1 (en) | 2013-08-30 |
IL227407B (en) | 2018-01-31 |
EP2663558A1 (en) | 2013-11-20 |
MX2013008163A (es) | 2013-08-27 |
US20120184741A1 (en) | 2012-07-19 |
WO2012097270A1 (en) | 2012-07-19 |
ZA201305230B (en) | 2014-11-26 |
AR084862A1 (es) | 2013-06-26 |
TW201309676A (zh) | 2013-03-01 |
MX351555B (es) | 2017-10-19 |
CL2013002026A1 (es) | 2013-12-27 |
AU2012205416B2 (en) | 2017-02-02 |
AU2012205416A1 (en) | 2013-08-01 |
IL227407A0 (en) | 2013-09-30 |
RU2013137753A (ru) | 2015-02-20 |
US20130317222A1 (en) | 2013-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013017977A2 (pt) | formas sólidas de inibidor de girase (r) 1-etil-3-[5-[2-{1-hidroxi-1-metil-etil}pirimidin-5-il]-7-(tetrai-drofuran-2-il)-1h-benzimidazol-2-il]ureia | |
BR112015022861A8 (pt) | inibidores de bromodomínio | |
BR112012017402A2 (pt) | inibidores de vírus de flaviviridae | |
BR112012017382A2 (pt) | compostos inibidores de viroses flaviviridae, uso dos mesmos e composição farmacêutica | |
BR112015022643A2 (pt) | inibidores diidro-pirrolpiridinona | |
BR112014008495A2 (pt) | inibidores de proteína quinase | |
BR112015003592A2 (pt) | derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas | |
BR112015032693A2 (pt) | inibidores de bromodomínio | |
BR112014001801A2 (pt) | indazóis | |
BR112015008325A2 (pt) | compostos antivirais contra o rsv | |
BR112014013661A8 (pt) | derivados de nucleosídeos 2,4-difluoro-2-metil substituídos como inibidores de replicação de hcv-rna | |
BR112013032711A2 (pt) | composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase | |
BR112014005226A2 (pt) | derivados de benzonitrila como inibidores de cinase | |
MX341342B (es) | Formas solidas del inhibidor de girasa (r)-1-etil-3-[6-fluoro-5-[2 -(1-hidroxi-1-metil-etil) pirimidin-5-il]-7-(tetrahidrofuran-2-il) -1h-benzimidazol-2-il]urea. | |
BR112014000938A2 (pt) | quinazolinas substituídas, a preparação das mesmas e o uso das mesmas em composições farmacêuticas | |
BR112014029115A8 (pt) | Composto, composição farmacêutica, e, uso de um composto ou composição | |
RS54072B1 (en) | COMPOSITIONS FOR USE IN THE TREATMENT OF Viral INFECTIONS | |
BR112018067930A2 (pt) | composto, sal de ácido trifluoroacético, composição farmacêutica, método para tratamento de uma infecção bacteriana, e, uso de um composto. | |
BR112013031405A2 (pt) | piridopirazinas substituídas como novos inibidores de syk | |
BR112013029999A2 (pt) | derivados de tiazol | |
BR112013031402A2 (pt) | derivados de hidantoína como inibidores de kv3 | |
BR112014002958A2 (pt) | "3,4-di-hidro-1h-[1,8]naftiridinonas substituídas com piperidinila antibacterianas, composição farmacêutica compreendendo os referidos compostos, processos para preparação destes e uso". | |
BR112015012825A2 (pt) | piridopirazinas substituídas como inibidores de syk | |
UA109290C2 (uk) | Спільні кристали і солі інгібіторів ccr3 | |
BR112013017362A2 (pt) | composto de fórmula (i), processo para preparar um composto de fórmula (i), composição farmacêutica e compostos, métodos e usos inovadores |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |